Skip to main content
SpringerLink
Log in

Inhibitor eradication in refractory acquired hemophilia with lenalidomide

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kuhne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkuhler K, Kalus U, Blumtritt JM, Werwitzke S, Budde E, Koch A, Knobl P (2015) Prognostic factors for remission of and survival in acquired hemophilia A (AHA). Results from the GTH-AH 01/2010 study. Blood 125(7):1091–1097. https://doi.org/10.1182/blood-2014-07-587089

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Collins P, Baudo F, Knoebl P, Levesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kuhne A, on behalf of the EACH2 registry collaborators (2012) Immunosuppression for acquired hemophilia A. Results from the European Acquired Haemophilia Registry (EACH2). Blood 120(1):47–55. https://doi.org/10.1182/blood-2012-02-409185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Brás GP, Pinto RJSM, Carvalho MMMC, Fernandes S, Andrade J, Guimarães J (2017) Bortezomib. Potential key role in the treatment of multiple myeloma-related acquired hemophilia a. Semin Thromb Hemost 43(1):109–112. https://doi.org/10.1055/s-0036-1597648

    Article  CAS  PubMed  Google Scholar 

  4. McFadyen JD, Tran H, Kaplan ZS (2017) Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol 178(6):986–987. https://doi.org/10.1111/bjh.14185

    Article  CAS  PubMed  Google Scholar 

  5. Pellom ST, Dudimah DF, Thounaojam MC et al (2015) Modulatory effects of bortezomib on host immune cell functions. Immunotherapy 7(9):1011–1022. https://doi.org/10.2217/imt.15.66

    Article  CAS  PubMed  Google Scholar 

  6. Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 1(1):31–35. https://doi.org/10.1182/bloodadvances.2016001412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474–1478. https://doi.org/10.1136/annrheumdis-2014-206016

    Article  CAS  PubMed  Google Scholar 

  8. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64(2):493–503. https://doi.org/10.1002/art.33333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M (2017) Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells. Oncotarget 8(58):98200–98214. https://doi.org/10.18632/oncotarget.21516

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhang L, Bi E, Hong S, Qian J, Zheng C, Wang M, Yi Q (2015) CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget 6(34):36032–36040. https://doi.org/10.18632/oncotarget.5506

    Article  PubMed  PubMed Central  Google Scholar 

  11. Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M (2016) Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. Ann Hematol 95(11):1805–1810. https://doi.org/10.1007/s00277-016-2775-y

    Article  CAS  PubMed  Google Scholar 

  12. Lopez-Millan B, La Diaz de Guardia R, Roca-Ho H, García-Herrero CM, Lavoie JR, Rosu-Myles M, Gonzalez-Rey E, O'Valle F, Criado G, Delgado M, Menendez P (2017) Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med 49(2):e290. https://doi.org/10.1038/emm.2016.143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wu EY, Schanberg LE, Wershba EC, Rabinovich CE (2017) Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. Lupus 26(6):646–649. https://doi.org/10.1177/0961203316676377

    Article  CAS  PubMed  Google Scholar 

  14. Montefusco V, Galli M, Spina F, Stefanoni P, Mussetti A, Perrone G, de Philippis C, Dalto S, Maura F, Bonini C, Rezzonico F, Pennisi M, Roncari L, Soldarini M, Dodero A, Farina L, Cocito F, Caprioli C, Corradini P (2014) Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma. Selective occurrence after lenalidomide. Leuk Lymphoma 55(9):2032–2037. https://doi.org/10.3109/10428194.2014.914203

    Article  CAS  PubMed  Google Scholar 

  15. Loree JM, Cai E, Sheffield BS, Dutz JP, Villa D, Shepherd LE, Connors JM, Sehn LH, Savage KJ (2017) Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leuk Lymphoma 58(3):711–714. https://doi.org/10.1080/10428194.2016.1204657

    Article  PubMed  Google Scholar 

  16. Saburi M, Ohtsuka E, Itani K, Nagamatsu K, Ikebe T, Miyazaki Y, Ogata M, Saburi Y (2015) Development of acquired hemophilia a during treatment of multiple myeloma with lenalidomide. Rinsho Ketsueki 56(5):496–500. https://doi.org/10.11406/rinketsu.56.496

    Article  PubMed  Google Scholar 

  17. Braga WMT, da Silva BR, de Carvalho AC et al (2014) FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother 63(11):1189–1197. https://doi.org/10.1007/s00262-014-1589-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ, Owen RG, Selby PJ, Cook G (2009) CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(−)CD8(−)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144(5):686–695. https://doi.org/10.1111/j.1365-2141.2008.07530.x

    Article  PubMed  Google Scholar 

  19. Saurwein-Teissl M, Lung TL, Marx F, Gschosser C, Asch E, Blasko I, Parson W, Bock G, Schonitzer D, Trannoy E, Grubeck-Loebenstein B (2002) Lack of antibody production following immunization in old age. Association with CD8+CD28- T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 168(11):5893–5899. https://doi.org/10.4049/jimmunol.168.11.5893

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hemostaseology, University Hospital Leipzig, Liebigstr. 20, 04103, Leipzig, Germany

    C. Pfrepper & S. Petros

  2. Division of Hematology and Oncology Leipzig, University Hospital Leipzig, Leipzig, Germany

    W. Poenisch

  3. Division of Rheumatology, University Hospital Leipzig, Leipzig, Germany

    M. Pierer

  4. Department of Cardiology, University Hospital Leipzig, Leipzig, Germany

    M. Metze

  5. Institute of Laboratory Medicine, University Hospital Leipzig, Leipzig, Germany

    T. Kaiser

Authors
  1. C. Pfrepper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Poenisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Pierer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Metze
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Petros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Pfrepper.

Ethics declarations

Conflict of interest

The authors declared that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Informed consent was obtained from the patient for being included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

On behalf of my co-authors, I state that the material is original research, has not been previously published, and has not been submitted for publication elsewhere while under consideration

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pfrepper, C., Poenisch, W., Pierer, M. et al. Inhibitor eradication in refractory acquired hemophilia with lenalidomide. Ann Hematol 98, 1533–1535 (2019). https://doi.org/10.1007/s00277-019-03620-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03620-2

Search

Navigation